Editor's Note: This video was filmed May 7th.

Biotechs Aegerion Phamaceuticals (NASDAQ:AEGR) and Isis Pharmaceuticals (NASDAQ:ISIS) reported earnings last week, and the market reacted pretty negatively to the news --  Isis lost about 4% after reporting, while Aegerion cratered 25%. Looking at the numbers, you might wonder if that was a transcription error.

After all, it was Isis whose revenue dropped to $28 million from $43 million in the year-ago first quarter. Isis also reported a wider loss, with a $0.27 loss per share comparing unfavorably to a $0.02 loss in first quarter of 2013. And Aegerion increased revenue -- in fact, it roughly doubled it to $40 million from $19 million in the year-ago quarter. And the company narrowed its net loss from $0.64 per share to $0.54 per share.

So, what happened?

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson lay out why Aegerion lost so much more than Isis -- how analyst expectations and weaker-than-expected sales of the drug Juxtapid combined to sink the stock last week.

This top stock could make perfect sense for your portfolio
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

David Williamson and Michael Douglass have no position in any stocks mentioned. The Motley Fool recommends Isis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.